We are pleased to announce the creation of LumiThera Diagnostics, a wholly owned subsidiary of LumiThera, Inc. Since first launching the Valeda Light Delivery System in Europe in 2018, we have been working to provide a novel treatment approach for patients with dry Age-related Macular Degeneration (AMD). Through the acquisition of Diopsys, Inc. and the MacuLogix assets (AdaptDx and AdaptDx Pro) in 2022, we also added the ability to diagnose and monitor progression of the disease. Now with Valeda treatments and the new diagnostics, LumiThera is taking a huge step forward in early degenerative eye care for patients, stated Clark Tedford, PhD, LumiThera President & CEO. LumiThera Diagnostics will be based at the former MacuLogix site in Middletown, Pennsylvania. The AdaptDx Pro is a simple, fully automated dark adaptometer. It measures dark adaptation speed, which can be used to identify AMD with 90% sensitivity.